Loading…
Hiding in plain sight
A common biomarker of pancreatic disease has a functional role in pathogenesis Pancreatic cancer remains one of the deadliest human malignancies. This is in part due to the lack of a reliable method of early detection, because late-stage disease is largely refractory to treatment. Biomarkers for ear...
Saved in:
Published in: | Science (American Association for the Advancement of Science) 2019-06, Vol.364 (6446), p.1132-1133 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | A common biomarker of pancreatic disease has a functional role in pathogenesis
Pancreatic cancer remains one of the deadliest human malignancies. This is in part due to the lack of a reliable method of early detection, because late-stage disease is largely refractory to treatment. Biomarkers for early disease detection have remained elusive. However, the glycan carbohydrate antigen 19-9 (CA19-9), which is produced by pancreatic cancer cells, is increased in the serum of most patients (
1
). It is clinically useful as a biomarker of tumor burden during treatment, rather than for early detection, because serum CA19-9 is also increased in other diseases, including inflammation of the pancreas (pancreatitis), a risk factor for the development of pancreatic cancer. To date, there has been little understanding of CA19-9 function in pancreatic pathophysiology. On page 1156 of this issue, Engle
et al.
(
2
) report that CA19-9 drives the development of pancreatitis and accelerates pancreatic tumor progression. |
---|---|
ISSN: | 0036-8075 1095-9203 1095-9203 |
DOI: | 10.1126/science.aax9341 |